Clinical trials: sponsored by AbbVie
Healthy Volunteers
A Study to Compare the Bioavailability of Intravenously Infused Risankizumab Manufactured by Two Different Processes in Healthy Adults
The objective of this study is to assess the bioavailability of risankizumab liquid vial manufactured with the new process (CMC3) relative to the current process (CMC2).
- Trial name
- NCT06054425
- Testing
- Risankizumab
- Where
- 3 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteer
A Study to Assess the Mass Balance of [14C] ABBV-552 in Healthy Male Participants Following Single Oral Dose Administration
The purpose of this study is to evaluate mass balance, pharmacokinetics and safety of [14C] ABBV-552 in healthy, male volunteers following administration of a single oral dose.
- Trial name
- NCT06278766
- Testing
- ABBV-552
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteers
Relative Bioavailability of Two Lutikizumab Formulations and Pharmacokinetics, Safety, and Tolerability of Lutikizumab in Chinese Participants
The purpose of this study is to compare the bioavailability of two different formulations of lutikizumab, and to assess adverse events (AEs) and how lutikizumab moves through the body in healthy Chinese participants.
- Trial name
- NCT06067568
- Testing
- Lutikizumab Dose A, Lutikizumab Dose B
- Where
- 3 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteers
Study to Assess Adverse Events and Compare How Crushed, Ground, and Intact Oral Tablets Venetoclax Moves Through the Body of Healthy Female Adult Volunteers
The objective of this study is to assess the oral bioavailability of crushed and ground venetoclax commercial tablets relative to the intact venetoclax commercial tablets under fed condition in healthy female participants.
- Trial name
- NCT05909553
- Testing
- Venetoclax
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteers
A Study to Assess Pharmacokinetics, Safety, and Tolerability of ABBV-903 in Healthy Japanese and Han Chinese Participants
The objective of this study is to assess the pharmacokinetics (PK), safety, and tolerability of ABBV-903 or placebo in healthy adult Japanese and Han Chinese subjects.
- Trial name
- NCT06009237
- Testing
- ABBV-903
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteer
A Study to Assess Drug-Drug Interaction Between ABBV-903 and Midazolam in Adult Healthy Volunteers
The main objective of this study is to assess the drug-drug interaction and pharmacokinetics of ABBV-903 and Midazolam in healthy adult participants.
- Trial name
- NCT05895266
- Testing
- ABBV-903, Midazolam
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteer
A Study to Assess Adverse Events and How Single and Multiple Ascending Doses of ABBV-903 Move Through the Body in Healthy Adults
The purpose of this study is to evaluate adverse events and tolerability of single and multiple doses of ABBV-903, and to assess how the drug moves through the body in healthy adult volunteers.
- Trial name
- NCT05691699
- Testing
- ABBV-903, Itraconazole
- Where
- United States
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteer
A Study to Assess the Mass Balance of [14C] ABBV-903 in Healthy Male Participants Following Single Oral Dose Administration
The purpose of this study is to evaluate the mass balance and safety of [14C] ABBV-903 in healthy male volunteers following a single oral dose administration.
- Trial name
- NCT05995366
- Testing
- ABBV-903
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteer
A Study to Assess the Relative Bioavailability of Immediate Release Formulations of ABBV-903 in Healthy Adult Participants
The main objective of this study is to assess the relative bioavailability and pharmacokinetics of ABBV-903 in healthy adult participants.
- Trial name
- NCT05836506
- Testing
- ABBV-903 Tablet Form 1, ABBV-903 Tablet Form 2
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteers
Study to Evaluate the Relative Bioavailability of Two Risankizumab Drug Product Presentations in Healthy Volunteers.
This study will assess how safe risankizumab is and how risankizumab moves through the body of adult healthy participants. Adverse Events will be assessed.
- Trial name
- NCT05567029
- Testing
- Risankizumab Dose A, Risankizumab Dose B
- Where
- 5 sites in United States
- Volunteers
- 198 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteers
A Study to Assess the Adverse Events and How Oral ABBV-552 Capsules Moves Through the Body of Healthy Adult Japanese and Han Chinese Participants
This study will assess how safe ABBV-552 is and how ABBV-552 moves through the body of adult healthy Japanese and Han Chinese participants. Adverse Events will be assessed.
- Trial name
- NCT05686980
- Testing
- ABBV-552
- Where
- 2 sites in United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- AbbVie
ABBV-154
Study to Assess Adverse Events and Compare How Two Subcutaneous ABBV-154 Injection Formulations Move Through the Body of Adult Healthy Participants
This study will assess how safe ABBV-154 is and how ABBV-154 moves through the body of adult healthy participants. Adverse Events will be assessed.
- Trial name
- NCT05556226
- Testing
- ABBV-154 Dose Formulation A, ABBV-154 Dose Formulation B
- Where
- 2 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteers
A Study to Assess the Pharmacokinetics and Safety of Co-administered Oral Galicaftor, Navocaftor, and ABBV-576 in Healthy Adults for the Treatment of Cystic Fibrosis
Cystic Fibrosis (CF) is a rare, life-threatening, genetic disease that affects the lungs and digestive system, significantly impairing the quality of life, with those affected having a median age of death at 40.
- Trial name
- ABBV-576 DDI (NCT05530278)
- Testing
- Galicaftor, ABBV-576, Navocaftor
- Where
- 4 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteers
A Study to Assess How Food Affects the Safety and Pharmacokinetics of Galicaftor and Navocaftor
Cystic Fibrosis (CF) is a rare, life-threatening, genetic disease that affects the lungs and digestive system, significantly impairing the quality of life, with those affected having a median age of death at 40.
- Trial name
- M23-492 FE (NCT05538585)
- Testing
- Galicaftor, Navocaftor
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AbbVie
Hepatic Impairment
A Study to Assess Safety of Cedirogant and How Cedirogant Moves Through the Body in Adult Participants With Mild, Moderate and Severe Hepatic Impairment
The objective of this study is to evaluate the pharmacokinetics and safety of cedirogant following oral administration of multiple doses in adult participants with hepatic impairment and normal hepatic function.
- Trial name
- NCT05376839
- Testing
- Cedirogant
- Where
- 3 sites in United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteers
Study to Assess Adverse Events and How Oral ABBV-990 Moves Through the Body of Adult Healthy Participants
This study will assess how safe ABBV-990 is and how ABBV-990 moves through the body of adult healthy participants. Adverse Events will be assessed.
- Trial name
- NCT05475821
- Testing
- ABBV-990
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AbbVie
Renal Impairment, Renal Disease
Study to Assess Adverse Events and the Movement of Oral Venetoclax Tablet Through the Body of Female Participants Aged 18-75 Years With Impaired Renal Function
Renal insufficiency is common in participants with blood cancers. The main objective of this study is to evaluate adverse events and movement of oral venetoclax tablets through the body of female participants with severe normal…
- Trial name
- NCT04810598
- Testing
- Venetoclax
- Where
- 2 sites in United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AbbVie
Cognitive Disorders
A Single Ascending Oral Dose Study of SDI-118 in Healthy Male Subjects Including an Assessment of Receptor Occupancy and Food Effect
This is a First-in-Human, Randomized, Placebo-controlled, Single Ascending Oral Dose Study of SDI-118 in Healthy Male Subjects including Receptor Occupancy Measurements after Single Dose of SDI-118 and an Assessment of Food…
- Trial name
- NCT05486195
- Testing
- SDI-118
- Where
- Belgium
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteers
A Study in Healthy Japanese and Caucasian Subjects to Assess the Pharmacokinetics, Safety and Tolerability of Risankizumab
The main objective of this study is to assess the pharmacokinetics, safety, tolerability and immunogenicity following a single intravenous (IV) infusion of risankizumab in healthy Japanese and Caucasian participants.
- Trial name
- NCT05305222
- Testing
- Risankizumab
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteers
A Study to Evaluate the Bioavailability of Risankizumab in Pre-filled Syringe or Auto-injector in Healthy Adult Participants
The objective of this study is to evaluate the bioavailability of risankizumab new formulation in prefilled syringe (PFS) relative to the 90 mg/mL formulation in PFS in healthy volunteers.
- Trial name
- NCT05283681
- Testing
- Risankizumab
- Where
- 2 sites in United States
- Volunteers
- 226 people, healthy volunteers welcome
- Sponsor
- AbbVie